KRAS and neoplasm: In further support of this, the majority of all disseminating primary tumour subclones, across treated samples, showed significant resistance to therapy (see Materials and methods for quantification of ‘therapy resistance’), with significant resistance in ARID1B (MIM: 614556), BMPR2 (MIM: 600799), CREBBP (MIM: 600140), ERBB2 (MIM: 164870), FAT4 (MIM: 612411), KRAS, and MAP2K4 (MIM: 601335), amongst other driver mutations (Table 2 and Table S5, Figure 4).